NCT06035055View on ClinicalTrials.gov

Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

October 31, 2023

Study Completion Date

January 31, 2024

Conditions
BronchiectasisCystic FibrosisPseudomonas AeruginosaBurkholderia Cepacia Infection
Interventions
DRUG

Ceftolozane/tazobactam

9g ceftolozane/tazobactam in 240 millilitres 0.9% sodium chloride IV infusion given over 24 hours for 10-14 days

Sponsors

Collaborators (1)

Mater
All Listed Sponsors
collaborator

The Prince Charles Hospital

OTHER_GOV

collaborator

Mater

OTHER

lead

Sunshine Coast Hospital and Health Service

OTHER

NCT06035055 - Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis | Biotech Hunter | Biotech Hunter